Aseda Sciences

Executive Summary

Aseda Sciences is a Swiss biotech company leveraging integrated phenotypic screening and AI to predict compound toxicity, thereby enabling safer drug design and reducing reliance on animal testing. Founded in 2017 and based in Basel, the company targets neuroscience and rare disease applications, offering a platform that identifies toxicity risks earlier in the development pipeline. This approach aims to improve productivity for chemical industries, enhance patient safety, and safeguard the environment. By combining cellular assays with machine learning, Aseda provides a data-driven solution to a critical bottleneck in drug development—late-stage attrition due to safety issues. As a private, early-stage company, its value proposition aligns with industry trends towards the 3Rs (Replacement, Reduction, Refinement of animal testing) and AI-driven drug discovery. While specific funding details are undisclosed, the company's technology has potential applications across pharmaceutical, agrochemical, and cosmetic sectors.

Upcoming Catalysts (preview)

• Q3 2026Strategic Partnership with a Major Pharma Company for Toxicity Screening Services60% success
• Q4 2026Series A Financing Round to Scale Platform and Expand Commercial Reach70% success
• Q2 2026Release of Enhanced AI Model Incorporating Multi-Omics Data50% success